CAJ | 학술논문

目的：制备树突状细胞与肺癌细胞A549融合疫苗，分析其应用效果。方法选择DC和A-549细胞，以50％聚乙二醇和10％二甲基亚砜为融合剂，构建融合细胞，观察融合效果。同时采用流式细胞仪检测相关免疫因子的变化。结果DC细胞存活率为（90．62±5．22）％，DC-A549融合细胞融合率为（25．36±3．23）％。DC-A549融合细胞与淋巴细胞共培养的 T淋巴细胞其CD8＋ T淋巴细胞含量高于单独培养淋巴细胞，CD4＋ T淋巴细胞含量低于单独培养淋巴细胞，差异有统计学意义（P＜0．05）。结论树突状细胞与肺癌细胞A549融合疫苗能刺激免疫细胞活化，有可能在临床上获得抗肺癌的能力。
목적：제비수돌상세포여폐암세포A549융합역묘，분석기응용효과。방법선택DC화A-549세포，이50％취을이순화10％이갑기아풍위융합제，구건융합세포，관찰융합효과。동시채용류식세포의검측상관면역인자적변화。결과DC세포존활솔위（90．62±5．22）％，DC-A549융합세포융합솔위（25．36±3．23）％。DC-A549융합세포여림파세포공배양적 T림파세포기CD8＋ T림파세포함량고우단독배양림파세포，CD4＋ T림파세포함량저우단독배양림파세포，차이유통계학의의（P＜0．05）。결론수돌상세포여폐암세포A549융합역묘능자격면역세포활화，유가능재림상상획득항폐암적능력。
Objective To prepare A549 fusion vaccine of dendritic cells and lung cancer cells ,and analysis its application results .Methods Selected and DC and A-549 cell were built and the effect was observed by the 50% polyethylene glycol and 10% DMSO as the fluxing agent .While used flow cy-tometry to detect immune factors related changes .Results The DC cell viability was (90 .62 ± 5 . 22)% ,the fusion rate of DC-A549 cells was (25 .36 ± 3 .23)% .The CD8+ T lymphocytes of the DC-A549 cells and lymphocytes were higher than those cultured alone lymphocytes ,so that was lower for the CD4+ T lymphocytes and there were statistical significantly differences (P< 0 .05) .Conclusion Dendritic cells and A549 cells fusion vaccine has the ability to stimulate immune cell activation ,resul-ting in clinical access to anti-cancer abilities .